Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
Active, not recruiting · NCT06189638 · Registry updated 2025-05-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers | Diabetes Complications, Diabetic Foot, Foot Ulcer, Infections, Leg Ulcer, Skin Ulcer, Skin and Connective Tissue Diseases, Wound Infection, cardiovascular disorder, diabetes mellitus, diabetic neuropathy, diabetic peripheral angiopathy, endocrine system disorder, skin disorder, vascular disorder | Active, not recruiting | Phase 2 | 2025-05-25 | NCT06189638 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. | 1 |
| Parexel | 41 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Bioresearch Partner Holdings, LLLP | Miami | United States | 1 |
| ILD Research Center | Vista | United States | 10 |
| Santos Research Center, CORP | Tampa | United States | 4 |